Golidocitinib not checked
Dizal Pharmaceuticals · AZD4205
FollowEvery change as it happens, and a Monday email
Trials
2 active
6 in total
Targets
—
None known yet
What this is
- How it works
- Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.-citinib: Janus kinase inhibitors WHO name stem
- How it’s given
- “150 mg, orally, once daily, with or without food, in a 21-day cycle”In the company’s words, NCT07234162 on ClinicalTrials.gov
- Tested for
- Peripheral T-cell Lymphoma, T-cell Lymphomas
- Main trialPhase 3
- “This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically confirmed PTCL who have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen(s).”In the company’s words, NCT07234162 on ClinicalTrials.gov
- Other names
- AZD4205
Other drugs for Peripheral T-cell Lymphoma
- XNW5004Evopoint Biosciences Inc. · Phase 3
- SoquelitinibCorvus Pharmaceuticals, Inc. · Phase 3
- Liposomal mitoxantrone hydrochlorideCSPC · Phase 3
- DuvelisibSecuraBio · Phase 3
- BelinostatAcrotech Biopharma Inc. · Phase 3
- PralatrexateAcrotech Biopharma Inc. · Phase 3
Coming up2
- 30 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- Sep 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Nov 2027 | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) | |
| Phase 1/2Recruiting | Sep 2029 | Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) | |
| Phase 2Completed | 31 Mar 2025 | AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) | |
| Phase 2Completed | 17 Oct 2025 | AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) | |
| Phase 1/2Completed | 12 Oct 2023 | Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) | |
| Phase 1Completed | 8 Oct 2022 | Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026